Life Sciences

  • April 15, 2026

    NC Judge Won't Undo $4M Philips Copyright Verdict

    A North Carolina federal judge has refused to erase a $4 million jury verdict against independent service organization Transtate Equipment Co. for violations of the Digital Millennium Copyright Act, saying trial evidence provided a "firm basis" to support the jury's statutory damages award.

  • April 15, 2026

    Willkie Adds O'Melveny Litigator To Los Angeles Office

    Willkie Farr & Gallagher LLP expanded its Los Angeles office with the recent addition of a litigator who moved her practice after nearly 15 years with O'Melveny & Myers LLP.

  • April 15, 2026

    Biopharma Co. Says Ex-Worker Used Files To Build AI Rival

    A biopharmaceutical consulting firm's ex-contractor illegally downloaded thousands of proprietary internal files and emails that he then used to launch a rival company powered by artificial intelligence, the firm claimed in a lawsuit, alleging that the former contractor violated federal trade secrets law.

  • April 14, 2026

    Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told

    Hedge fund Armistice Capital and two of its executives exploited the COVID-19 pandemic to issue press releases that falsely inflated their controlling share in pharmaceutical company Vaxart, then dumped the shares for $250 million before the bottom fell out, investors told a California federal jury at the start of trial Tuesday.

  • April 14, 2026

    4th Circ. Revives Pharma Bid To Block Maryland's 340B Law

    A split Fourth Circuit panel on Tuesday tossed a Maryland district court's order denying a preliminary injunction to pharmaceutical manufacturers that have challenged a state law addressing drug delivery in the federal 340B discount program, pointing to its recent ruling that West Virginia's similar statute is likely preempted.

  • April 14, 2026

    States Denied Time For Talks To Settle Drug Price-Fixing Suit

    A Connecticut federal judge Tuesday denied a request by dozens of U.S. states to freeze their antitrust case against generic-drug manufacturers, a pause the states argued would allow the parties to focus on settlement talks rather than pending discovery and motion deadlines.

  • April 14, 2026

    Justices Told That Eli Lilly's FCA Qui Tam Challenge Too Late

    A whistleblower who secured a $183 million trial win against Eli Lilly urged the U.S. Supreme Court on Tuesday to reject its constitutional challenge over his ability to sue for the federal government, arguing the drugmaker's arguments came too late.

  • April 14, 2026

    Trade Group Latest To Sue Wash. Over 340B Drug Pricing Law

    Pharmaceutical Research and Manufacturers of America claims a new Washington state law attempts to illegally reshape the federal 340B Drug Pricing Program and singles out participating drugmakers with burdensome regulations, according to a fresh federal lawsuit that follows similar constitutional challenges mounted by Novartis and AbbVie.

  • April 14, 2026

    Vertex Sues Former Exec To Block Move To Rival

    Vertex Pharmaceuticals asked a Massachusetts state court judge to bar a former executive from taking a virtually identical role at competitor Vera Therapeutics, citing a noncompete agreement he allegedly signed.

  • April 14, 2026

    FDA Offers Guidance On Safety Testing For Gene-Editing Tech

    The U.S. Food and Drug Administration on Tuesday issued draft guidance recommending steps drug companies should take to evaluate the safety of gene-editing technology as they seek federal approval for cutting-edge treatments aimed at genetic diseases.

  • April 14, 2026

    3rd Circ. Upholds J&J Injunction Bid Loss In Biosimilar Fight

    The Third Circuit on Tuesday ruled that a Johnson & Johnson subsidiary couldn't justify its bid for an order blocking Samsung Bioepis from paving the way for a Cigna unit to launch a generic version of an anti-inflammatory treatment.

  • April 14, 2026

    Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal

    Venture-backed pre-clinical biotechnology firm CrossBridge Bio Inc., advised by Cooley LLP, on Tuesday announced that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal worth up to $300 million.

  • April 14, 2026

    Mich. AG Says PBMs Can't Duck Drug-Pricing Suit

    Two pharmacy benefit managers can't dodge an antitrust lawsuit accusing them of price-fixing reimbursement rates because Michigan has properly claimed an antitrust violation, state Attorney General Dana Nessel told a federal court, asking it to toss aside the PBMs' dismissal bid. 

  • April 14, 2026

    4th Circ. Won't Rehear Allergan Overcharge Suit

    The Fourth Circuit on Tuesday denied a rehearing petition lodged after a panel revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid.

  • April 14, 2026

    Buyers Seek Final Approval Of $4.85M Bayer Benzene Deal

    A class of consumers is asking a New Jersey federal court to give final approval of a $4.85 million settlement to resolve claims that Bayer US LLC's antifungal products were contaminated with benzene.

  • April 14, 2026

    Avanos Medical Going Private In $1.3B Deal Led By 3 Firms

    American Industrial Partners has agreed to acquire Avanos Medical Inc. in an all-cash transaction valued at nearly $1.3 billion, a take-private deal steered by three law firms, Avanos announced Tuesday. 

  • April 14, 2026

    State AGs, Albertsons Chain Reach $773M Opioid Deal

    Albertsons Cos. Inc. and the attorneys general of California, Colorado, Illinois and Oregon on Tuesday said that the pharmacy and grocery chain had agreed to a $773 million settlement in principle to end claims brought by states, local governments and Native American tribes over its role in the opioid crisis.

  • April 14, 2026

    Omnicare OK'd For Ch. 11 Auction With $250M Base Bid

    Pharmacy services provider Omnicare's choice of a $250 million stalking horse bid for its assets was approved Tuesday by a Texas bankruptcy judge, setting up a possible auction in May.

  • April 13, 2026

    Oracle Wins TRO Against Ex-Worker Threatening Secrets Sale

    A North Carolina federal judge Monday issued a temporary restraining order barring a recently laid-off Oracle sales employee from disclosing trade secrets that the software firm alleges he has threatened to sell to the "highest bidder" unless he receives an "unreasonable" fee.

  • April 13, 2026

    Citron's 'Shadowy Gang' Sued Over Short Selling Campaign

    Shareholders of PolarityTE have alleged in a new suit that "members of a shadowy gang of short sellers" conspired to short the biotechnology company's stock through targeted negative media attacks with Citron Research to enrich themselves at the expense of the shareholders, and that they ultimately caused the company's bankruptcy.

  • April 13, 2026

    Ill. Judge Wants More Proof To Recalculate Kickback Damages

    An Illinois federal judge tasked with recalculating damages from a home health company's referral kickback scheme said Monday that she needs more complete and reliable evidence to help determine the appropriate amount, but allowed the government to continue offsetting Medicare payments as part of its judgment collection bid.

  • April 13, 2026

    FTC Ends Teen Height Growth Supplement Claims

    A supplement maker and its owners agreed to pay $750,000 to end claims they misled customers into thinking their products could make their children taller, the Federal Trade Commission announced on Monday.

  • April 13, 2026

    Del. Judge Ends 80K Pre-2026 Zantac Cases

    A Delaware state court on Monday dismissed more than 80,000 suits filed before December alleging that Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, following a Delaware Supreme Court ruling on admissibility of the plaintiffs' experts.

  • April 13, 2026

    Obesity Drugmaker Leads 2 Biotech Startups Eyeing IPOs

    Two biotechnology startup companies on Monday filed plans for their public debuts, with obesity-focused Kailera Therapeutics planning to raise an estimated $500 million in its initial public offering and protein biomarker detection platform Alamar Biosciences planning to raise around $150 million.

  • April 13, 2026

    Mylan Can't Revive Copaxone Antitrust Claims Against Teva

    A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.

Expert Analysis

  • Series

    Judges On AI: How Judicial Use Informs Guardrails

    Author Photo

    U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.

  • What US Cos. Must Know To Comply With Italy's AI Law

    Author Photo

    Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.

  • Ag Bill Wording Presents Existential Threat To Hemp Industry

    Author Photo

    A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.